AUPH logo

AUPH Aurinia Pharmaceuticals Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$15.73
-0.48 (-2.96%)

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved…

Market Cap: $2.11Bwww.auriniapharma.com

Price

No data yet.

Social Signal Score

66
5d
—
30d
68
2 mentions
—
60d
65
3 mentions
—
90d
65
3 mentions
—
news: 3

Analyst Ratings

16 analysts
Buyconsensus
Strong Buy 0Buy 12Hold 4Sell 0Strong Sell 0
Avg price target$17+8.1%
Low $16Median $17High $18
Current Consensus

Revenue

$83.70M+278896.67%
$29.0K$27.92M$55.81M$83.70M
Dec 2016Sep 2026

Analyst Estimates

FY2025
$0.78
$0.74–$0.81
5 analysts
FY2026
$0.97+24% YoY
$0.93–$1.00
4 analysts
FY2027
$1.16+20% YoY
$1.12–$1.20
4 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
Kevin C. Tang
Sector
Healthcare
Industry
Biotechnology
Employees
128
Beta
1.41
Country
CA
Piotroski score
6 / 9 (Middling)
Altman Z-score
8.40
www.auriniapharma.com